written by Michael O’Leary
Another first-in-class drug is wending its way through the clinical trials process aimed at winning FDA approval for the treatment of type 2 diabetes. In early studies the drug, TAK-875, has been shown to lower HbA1c at rates similar to glimepiride (Amaryl).
TAK-875 is the first drug to reach clinical development that is aimed at blocking the GPR40 protein as a way to reduce insulin production.
(Link to published site)
Another first-in-class drug is wending its way through the clinical trials process aimed at winning FDA approval for the treatment of type 2 diabetes. In early studies the drug, TAK-875, has been shown to lower HbA1c at rates similar to glimepiride (Amaryl).TAK-875 is the first drug to reach clinical development that is aimed at blocking the GPR40 protein as a way to reduce insulin production.
(Link to published site)
